Previous research has demonstrated that a triple-combination therapy using the anti-NKG2A monoclonal antibody monalizumab, the arginase inhibitor AZD0011, and the anti-PD-1 antibody could significantly improve the complete response rate in tumor-bearing mice, providing critical evidence for clinical translation [222]. Here, PDCD1 is linked to neoplasm.